Who is sponsoring HCC?

HCC is sponsored by Immunitor LLC.

What condition does HCC study?

HCC studies HCC, Liver Cirrhosis.

What drugs are being tested in HCC?

Interventions: Daily oral dose of hepcortespenlisimut-L.

Last reviewed 2019-08-29 · How we verify

Open Label Trial of Hepcortespenlisimut-L (V5) Immunotherapy for HCC

NCT02256514 Phase 2 UNKNOWN

The purpose of this study is to evaluate daily dosing of oral immunotherapy hepcortespenlisimut-L (V5) in patients with advanced stage of HCC not amenable to surgical intervention or with recurrent tumor after surgery.

Details

Lead sponsor	Immunitor LLC
Phase	Phase 2
Status	UNKNOWN
Enrolment	120
Start date	2014-09
Completion	2019-12

Conditions

HCC
Liver Cirrhosis

Interventions

Daily oral dose of hepcortespenlisimut-L

Primary outcomes

Effect of hepcortespenlisimut-L (V5) immunotherapy on serum levels of AFP (IU/ml) compared to baseline — minimum 3 months
monthly check-up of AFP serum levels
Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance — minimum 3 months
Comparison of abdominal CT scans at baseline and 3 months later

Countries

Mongolia